Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10811016rdf:typepubmed:Citationlld:pubmed
pubmed-article:10811016lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10811016lifeskim:mentionsumls-concept:C0079633lld:lifeskim
pubmed-article:10811016lifeskim:mentionsumls-concept:C1155065lld:lifeskim
pubmed-article:10811016lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:10811016lifeskim:mentionsumls-concept:C1446409lld:lifeskim
pubmed-article:10811016lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:10811016pubmed:issue5lld:pubmed
pubmed-article:10811016pubmed:dateCreated2000-6-1lld:pubmed
pubmed-article:10811016pubmed:abstractTextWe investigated whether pertussis toxin (PT)-sensitive heterotrimeric Gi proteins (Gi1, Gi2, Gi3) are involved in the regulation of TCR-induced activation of human T cells. First, Gi proteins were inactivated by PT: pretreatment with PT of purified blood T lymphocytes before CD3 cross-linking inhibited cell proliferation (-71.1 +/- 22.0%, P < 0.001), production of interleukin-2 (IL-2; -47.3 +/- 12.6%, P = 0.008), and expression of CD25 (-24.6 +/- 11.7%, P < 0.001) and CD69 (-25.7 +/- 9.0%, P < 0.001). Then, to identify which of the three Gi was involved, Gi1, Gi2, and Gi3 proteins were specifically inactivated by stably transfecting dominant-negative mutated forms of their alpha subunit in Jurkat cells. After activation, IL-2 production and CD69 expression were inhibited only in cells expressing inactive Gi2. We then studied the effects of interleukin-8 (IL-8), a CXC-chemokine with receptors coupled to Gi2 and produced in an autocrine fashion by activated T cells. Although its effects varied among donors, exogenous IL-8 stimulated proliferation and CD25 expression (up to, respectively, 200 and 77%) of PB T lymphocytes in response to CD3 activation, in a PT-sensitive manner. IL-8 also stimulated IL-2 production (by up to 42%) and CD69 expression, although weakly (+27%). Anti-human IL-8 antibody inhibited proliferation (-43%) and CD25 up-regulation (-45%) of activated T lymphocytes. In summary, several major responses of human T lymphocytes to TCR-mediated activation are regulated by Gi2 proteins, which for this function can be activated by IL-8 in an autocrine manner.lld:pubmed
pubmed-article:10811016pubmed:languageenglld:pubmed
pubmed-article:10811016pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:citationSubsetIMlld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10811016pubmed:statusMEDLINElld:pubmed
pubmed-article:10811016pubmed:monthMaylld:pubmed
pubmed-article:10811016pubmed:issn0741-5400lld:pubmed
pubmed-article:10811016pubmed:authorpubmed-author:JacquesYYlld:pubmed
pubmed-article:10811016pubmed:authorpubmed-author:LippertEElld:pubmed
pubmed-article:10811016pubmed:authorpubmed-author:HermouetSSlld:pubmed
pubmed-article:10811016pubmed:issnTypePrintlld:pubmed
pubmed-article:10811016pubmed:volume67lld:pubmed
pubmed-article:10811016pubmed:ownerNLMlld:pubmed
pubmed-article:10811016pubmed:authorsCompleteYlld:pubmed
pubmed-article:10811016pubmed:pagination742-8lld:pubmed
pubmed-article:10811016pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:meshHeadingpubmed-meshheading:10811016...lld:pubmed
pubmed-article:10811016pubmed:year2000lld:pubmed
pubmed-article:10811016pubmed:articleTitlePositive regulation of human T cell activation by Gi2 proteins and interleukin-8.lld:pubmed
pubmed-article:10811016pubmed:affiliationINSERM U463 Interactions Récepteurs-Ligands en Immunologie et Cancérologie, Institut de Biologie, Nantes, France.lld:pubmed
pubmed-article:10811016pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10811016pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10811016lld:pubmed